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Abstract The use of anabolic agents in livestock pro-
duction is a subject of much concern. Although prohibited
for more than 20 years within the EU, growth promoting
practices are still widely suspected. To meet the current
challenges for detecting illicit practices, ‘omics’ strategies
have recently been demonstrated as important new inves-
tigative tools. These investigations, based on the observa-
tion of physiological disturbances, mainly in urine,
demonstrated the possibility to monitor biomarkers
enabling high throughput determination of animal status in
terms of hormonal treatment. In this context, serum was
investigated for the first time as an alternative and potential
complementary sample type. A metabolomic approach
based on liquid chromatography coupled to high resolution
mass spectrometry, was exploited in order to, highlight
metabolic perturbations in serum of Revalor-XS (tren-
bolone acetate/estradiol) implanted bovines. Univariate and
multivariate statistical analyses were carried out to estab-
lish descriptive and predictive models. These models
enabled the discrimination of anabolised from control
animals, and highlighted a number of metabolites which
contributed the most in the observed discrimination. Fur-
ther, a screening model combining a set of selected
markers intensities was generated and it successfuly clas-
sified animals according to their status, up to 4 weeks post
Revalor-XS implant. This research indicates, for the first
time, that serum metabolomics has an important role in
screening to detect for anabolic misuse in bovines.
Keywords LC-HRMS metabolomics  Screening 
Steroids implant  Bovines  Serum
1 Introduction
The use of hormonal growth promoters (‘anabolic’) in
livestock production is still a current topic and a subject of
much debate. Very recently, in its newsletter published on
the 4th April 2014, Global Meat News reported that Russia
banned imports of both chilled and frozen beef from
Australia as Trenbolone (steroid) was detected during
inspections.
The main classes of growth promoters used in animal
production include: steroid hormones (steroids), b2-adren-
ergic substances (b-adrenergic agonists), and growth hor-
mones (somatotropins). In meat production, growth
promoters are used to increase productivity and to reduce
costs by improving weight gain and feed efficiency (Moran
et al. 1991; Lange et al. 2001). The purpose is to obtain more
edible muscle meat while not increasing production costs i.e.
to improve feed conversion rates and producing preferably
more tender (e.g. beef) and/or leaner (e.g. pork). Thus eco-
nomics is the main driver for growth promoter abuse
(Stephany 2010). International disputes on the potential
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detrimental effects to human health of growth promoter
residues carryover in foods still persist, leading to differing
legislation around the world. Their use was banned in animal
production in Europe (European Council Directive 88/146/
EC 1988) principally as a precautionary safety measure
(Serratosa et al. 2006). The history behind the ban can be
traced to a loss of European consumer confidence in meat
production due to a scandal involving illegal use of a steroid
(diethylstilbestrol) in Italy, which resulted in multiple cases
of breast development in young children aged 3–13 years
(Fara et al. 1979). This caused consumer organizations to
lobby for a blanket Europe-wide ban on all hormones.
Despite strong protests to the World Trade Organization
from other regions of the world, most notably from the
United States of America, arguing that it is a trade barrier
restricting the importation of their products from hormone-
treated animals to European Union (EU) markets (Mooney
et al. 2009; Stephany 2010).
At the time of the initial imposition of the ban, there
were only five licensed hormonal growth promoters: the
naturally occurring 17b-estradiol, testosterone and pro-
gesterone, and two synthetic hormones, trenbolone and
zeranol. Over time, people involved in these practices
turned to alternative compounds, alternative formulations
and alternative methods of administration to evade detec-
tion (Galbraith 2002).
Council Directive 96/23/EC (1996) and Commission
Decision 2002/65/EC lay down the requirements for resi-
due testing and performance of analytical methods in order
to ensure compliance with EU prohibition. Although pro-
hibited for more than 20 years within the EU, growth
promoting practices are still suspected (Courtheyn et al.
2002). The confirmation of anabolic compounds adminis-
tration is generally not an issue, though the screening stage
constitutes a limiting factor. To meet the current challenges
for screening illicit practices, ‘omics’ strategies, in partic-
ular metabolomics seems promising new tools (Riedmaier
et al. 2009, Pinel et al. 2010, Nebbia et al. 2011, Graham
et al. 2012). These approaches, based on the observation of
physiological perturbations, may offer a reliable solution to
tackle steroids abuse in livestock. Several metabolomics
studies reporting mass spectrometry based urinary finger-
printing to discriminate anabolised from control animals,
have shown this proof of concept for various screening
applications such as growth hormone (Kieken et al. 2009;
Boyard-Kieken et al. 2011), steroids (Rijk et al. 2009;
Dervilly-Pinel et al. 2011, 2012; Jacob et al. 2013) as well
as b-agonists (Courant et al. 2009; Dervilly-Pinel et al.
2014). Urine has primarily been the matrix of choice, due
to the non invasive nature of the sample collection.
In the scope of the present research, serum was inves-
tigated as an alternative biological fluid and its potential to
complement urine analysis was evaluated. Revalor-XS is
a new steroid combination implant which has been
approved in the United States for use in steers fed in
confinement for slaughter. Revalor-XS implant contains
200 mg trenbolone acetate and 40 mg estradiol as a slow
release delivery system which increases rate of weight gain
and improves feed efficiency for up to 200 days. The
delayed release of trenbolone acetate and estradiol elimi-
nates the need to re-implant cattle (FDA 2007). In beef
steers, the use of a combination of implants containing
trenbolone acetate and 17b-estradiol resulted in a 10–30 %
increase in average daily gain (ADG) and 5–15 %
improvement in body weight (BW) gain efficiency
(Duckett et al. 1997; Preston 1999).
Recently, Jacob et al. (2014) reported a metabolomics
workflow to compare cattle urinary metabolic profiles from
Revalor-XS implanted and non-implanted bovines. To
complement the urine metabolomics models, the present
study reports results obtained from an untargeted serum
metabolomics strategy to reveal Revalor-XS administra-
tion in bovines. Serum was assessed as the target matrix for
screening of anabolic practices. The final objective of these
studies is to reveal biomarkers of steroids administration
that will be further assessed for their potential to predict a
large range of steroid-based anabolic practices and that will
also allow extended detection time windows compared to
current strategies.
Liquid chromatography coupled to high resolution mass
spectrometry (LC-HRMS) analytical platforms were
employed for sera profiling, in polarity switching mode
HESI?/-; data generated were processed, univariate and
multivariate statistical analysis were performed, and models
were evaluated for their descriptive and prediction capabili-
ties. Further, a weighted equation combining a set of selected
markers intensities was determined, to predict sample coor-
dinates on the model and in the view of implementing the tool
as screening model. To the best of our knowledge, this is the
first time HRMS based metabolomics and serum have been
combined to investigate steroid abuse in cattle.
2 Materials and methods
The recommendations of the metabolomic standards ini-
tiative (MSI) (Sumner et al. 2007) were considered during
the present investigation, i.e., sample preparation, chro-
matography, MS, data processing and metabolite charac-
terization steps.
2.1 Animal experimentation and biological samples
collection
The experimentation was approved by the Animal Exper-
imentation Ethical Committee of the University of Bologna
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and carried out in accordance with the ethical standards
laid down in the 1964 Declaration of Helsinki and its later
amendments. The animal management also meets the cri-
teria of Directive 86/609/EEC regarding the protection of
animals used for experimental or other scientific purposes,
enforced by the Italian D Lgs n 116 of 27th January 1992
and Directive 63/2010.
Thirty-two 10–14 months male beef cattle (Charolaise
breed) were randomly divided into control (n = 16 ani-
mals) and treatment groups (n = 16 animals). Animals
were allowed a sixteen day acclimatization period, fol-
lowing which, each animal from the treatment group
received at day 0, a subcutaneous implant of Revalor-XS
(Merck Animal Health, NJ, USA), containing trenbolone
acetate (200 mg, i.e., 20 mg/pellet) and estradiol (40 mg,
i.e., 4 mg/pellet). Each implant contains ten pellets: four
uncoated and six coated. Animals were implanted once at
the start of the treatment, with the implant placed behind
the ear by means of special implanter (Revalor Gun) for
subcutaneous administration of the steroids. During the
experimentation, animals were normally fed; hay and water
were available ad libitum.
Blood samples were collected at regular time points, for
both treated (T) and control (C) animals, once a week over
a 10 week period following implant administration. The
blood was allowed to clot and serum was obtained by
centrifugation, frozen in liquid nitrogen and then stored at
-80 C. Data presented in the current study correspond to
sera collected on day 8, day 22 and day 29 post implant.
2.2 Chemical and reagents
All solvents and reagents used in this study were of ana-
lytical or HPLC grade quality. Acetonitrile (ACN), meth-
anol (MeOH), chloroform (CHCl3) were purchased from
Carlo Erba Reactifs (SDS, Peypin, France), and formic acid
was sourced from Merck (Briarele-Canal, France). Isotope
labeled standards, namely, Leucine-d3, L-tryptophan-d3,
Indole-acetic acid d5, 1,4-tetradecanedioic acid-d24 were
purchased from Sigma-Aldrich (Saint Quentin Fallavier,
France) and CDN Isotopes (Québec, Canada). MSCAL6
ProteoMass LTQ/FT-Hybrid, standard mixtures used for
external calibration of the MS instrument (positive and
negative ionization mode) were obtained from Sigma-
Aldrich (Saint Quentin Fallavier, France). The calibration
solution for the positive ionization mode, consisting of
caffeine, L-methionyl-arginyl-phenylalanyl-alanine ace-
tate, and Ultramark 1621, whilst for the negative ionization
mode, it consisted of sodium dodecyl stearate, taurocholic
acid sodium salt hydrate and Ultramark 1621. Water was
deionized and purified using an ultra pure water system
(Milli-Q, Millipore Corporation, Billerica, Massachusetts,
USA). For metabolite identification, commercially
available chemical reference standard of Dopamine was
purchased from Sigma-Aldrich (Saint Quentin Fallavier,
France).
2.3 Sample preparation
Prior to the extraction, serum samples were allowed to thaw
on ice. The extraction procedure firstly reported by Bligh
and Dyer (1959) and further re-adapted by Bird et al. (2011)
was employed. The first step in the sample preparation
scheme was a deproteinization step, which consisted of
removing high molecular weight species including proteins.
It was also employed as mean for preserving the LC–MS
system integrity and to reduce matrix effects. The depro-
teinization was achieved by organic solvent precipitation
using ice-cold methanol. The procedure consisted of a tri-
phasique liquid liquid extraction with MeOH:CHCl3:H2O.
Briefly, 190 ll of MeOH was added to 30 ll serum sample
and the mixture was vortex-mixed for 20 s. Next, 380 ll of
CHCl3 was added, the mixture was again vortexed for 20 s,
and finally, 120 ll of H2O to induce phase separation. The
sample was further mixed for 10 s and allowed to equili-
brate at room temperature for 10 min before centrifugation
(8,0009g, 10 min, 4 C). The upper MeOH phase was then
collected. An aliquot of the isotope labeled standards
(1.25 ng ll-1 each) was added to the MeOH phase in a 1:3
ratio; the mixture was evaporated to dryness at 35 C under
gentle nitrogen stream, and subsequently reconstituted with
H2O.
A pooled quality control (QC) sample, deriving from all
the study’ subject population was prepared, to ensure that
no or minimal metabolic information was lost (Want et al.
2010). QC samples were extracted along with each samples
batch and analysed throughout the analytical run, in order
to provide robust quality assurance for each metabolic
feature detected.
2.4 Liquid chromatography (LC)-high resolution mass
spectrometry (HRMS) instrumentation
A 1200 Infinity Series high performance liquid chroma-
tography (HPLC) system (Agilent Technologies, Santa
Clara, California, USA) coupled to an Exactive Orbitrap
mass spectrometer (Thermo Fisher Scientific, Bremen,
Germany) equipped with a heated electospray (H-ESI II)
source was used for sample analysis.
The chromatographic separation was achieved with a
XSelect CSH C18 (150 mm 9 2.1 mm; 3.5 lm particle
size, Waters, Dublin, Ireland) together with the corre-
sponding guard column, maintained at 35 C. Gradient
conditions were adapted from Dunn et al. (2011). The
mobile phase consisted of H2O in channel A, and MeOH in
channel B, both containing 0.1 % formic acid. The system
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was programmed to hold initial condition (97 % A) for
1 min, and then to perform gradient elution from 97 to 3 %
A over a 15 min period, hold at 3 % A for 4 min, return to
initial conditions over 2 min and then hold these conditions
for a further 5 min. The flow rate was 300 ll min-1 and
the injection volume was 5 ll.
The HPLC column was connected to the H-ESI interface
operating in polarity switch mode, i.e., both positive and
negative ionization mode.
High resolution MS fingerprints were acquired using the
following parameters: capillary voltage 30/-45 V, capil-
lary temperature 350 C, spray voltage 3/-3.5 kV, sheath
gas flow rate 55, auxiliary gas flow rate 10 a.u. (arbitrary
units), sweep gas flow rate 0, skimmer voltage 26/-26 V,
tube lens 100 V, heater temperature 300 C. Full scan mass
spectra were acquired from m/z 65 to 1,000 at a mass
resolving power of 50,000 Full Width at Half Maximum
(FWHM) at m/z 200. The scan speed was 2 Hz in profile
mode. Daily instrument calibration was performed using a
MSCAL6 ProteoMassT LTQ/FT-Hybrid ESI Pos/Neg
(Sigma–Aldrich). Xcalibur 2.2 (Thermo Fisher Scientific,
San Jose, CA, USA) was used for data acquisition and
analysis. Samples were analyzed by batch (day 8, day 22
and day 29) in randomized order.
Further, for the characterization of metabolite chemical
standard, MS/MS spectra were acquired on a hybrid
quadrupole-orbitrap (Q-ExactiveTM) mass spectrometer
(Thermo Fisher Scientific, Bremen, Germany).
2.5 Data processing and inter-batch normalization
LC-HESI (?/-) HRMS raw data files were initially pre-
processed with Xcalibur 2.2 (Thermo Fisher Scientific, San
Jose, CA, USA). The raw (*.raw) files were subsequently
converted to a more exchangeable format (*.mzXML) and
polarity split using MSConvert (Kessner et al. 2008) and
XCMS (Smith et al. 2006) software implemented with the R
language. Further data processing was performed using the
same software; multiple steps including: peak alignment,
peak picking, retention time alignment followed by a peak
grouping and integration step. The following parameters
were applied: CentWave algorithm (Tautenhahn et al. 2008);
peakwidth = 5–25; mzdiff = 0.001, mzwid = 0.008, and
minfrac = 0.85. The resulting XCMS matrix containing MS
features for each sample, was subsequently exported to
Excel for univariate analysis, inter-batch normalization and
later to SIMCA-P? (Version 13, Umetrics AB, Sweden)
software for multivariate statistical analysis.
Inter-batch normalization was applied to the collected
data from day 8, day 22 and day 29 for both controls and
Revalor-XS implanted animals; each sampling day cor-
responding to one analytical batch (sequence). The nor-
malization followed the procedure first described by van
der Kloet et al. (2009), assuming that the measurement
errors in a single batch are randomly distributed, and that
different batches can be compared and corrected using the
average or median value of the QC samples in a batch.
2.6 Data analysis
A combination of univariate and multivariate methods
were used to unveil relevant information. To examine the
MS features responsible for differences observed between
treated and control animals, a two-level data analysis was
performed. Sequences data from day 8, day 22 and day 29,
were first analyzed individually, and then MetaXCMS
(Tautenhahn et al. 2012a) was applied for second order
sample class comparison and to identify shared metabolites
across the study time points.
2.6.1 Univariate analysis
Univariate statistics were exploited to estimate instru-
mental variability. The coefficient of variation (CV) within
QC samples, was calculated using the standard deviation
divided by the mean intensities of each feature detected in
the QCs; a histogram of the resulting CV distribution was
plotted. Besides, retention time CVs and intensity CVs
were calculated for each labeled isotope standard.
Following this, computation of the fold change (ratio of
abundance observed between control and treated animals)
and the p value (statistical significance calculated from a
student t test) further served for metabolites selection. MS
features selection was based on the following criteria: CV
\30 %, p value \0.05 and fold change [1.5. It is worth
noting that these filters were considered when analyzing
individual sequences, i.e., samples from day 8, day 22 and
day 29, respectively. Whilst, only the criterion CV\30 %
was applied to the data resulting from MetaXCMS matrix.
Extracted ion chromatograms (EICs) visualization was
achieved in order to withdraw potential artifacts from the
ion list.
2.6.2 Multivariate statistical analysis
MetaXCMS was employed to identify shared metabolites
across the collection time points (day 8, day 22 and day 29).
The data matrix was subsequently exported to SIMCA-P?
and subjected to multivariate statistical analysis. In order to
reveal discriminating features and building descriptive and
predictive models, first, a Principal Component Analysis
(PCA) with logarithmically-transformed and Pareto scaling
was undertaken followed by, a supervised (Orthogonal)
Projection of Latent Structures (O)PLS. The PCA aims at
providing an overview of the data structure while the OPLS
models attempt to explain a Y variable (which in the present
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study represents the status of the animal, i.e., control or
Revalor-XS treated animals) from the X matrix of all the
ions constituting the fingerprint.
MS features (ions) were considered as independent
variables while days of experiment were assigned to the
dependent variables. The validation and robustness of each
model were evaluated by R2(Y) and Q2(Y) parameters,
cross validation-analysis of variance CV-ANOVA (Eriks-
son et al. 2008), and permutation test. Characteristics of the
resulting statistical model were exploited to generate an
equation based on combined individual abundances of a set
of selected markers. The model was further tested on the
data set for screening purposes.
2.7 Putative metabolites identification
First, metabolites of interest were identified by online
database searches. Accurate mass of each putative metab-
olite was submitted to databases for identification of the
corresponding metabolite. Metabolite hits were searched
against two databases, i.e. METLIN (Zhu et al. 2013;
Tautenhahn et al. 2012b, Smith et al. 2005) and HMDB
(Wishart et al. 2007, 2009, 2013). Metabolite hits were
searched for using a tolerance of ±0.001 Da (HMDB),
±5 ppm (METLIN), molecular species, charge state and
adduct types. Additionally, results generated after database
searches were assessed in relation to metabolites physio-
chemical properties, spectral similarities, matrix of occur-
rence and commercially available chemical reference
standards; commercially available reference standards were
purchased for metabolites with successful database hits.
3 Results and discussion
Regarding the efficiency of Revalor-XS treatment in the
current investigation, animal experiment outcomes have
recently been reported (Jacob et al. 2014). Briefly, a body
weight gain resulting in a conversion efficiency of 9.54 and
8.51 was noted, for controls and treated animals respec-
tively, attesting to the increased performances gained upon
such treatment. Release of trenbolone acetate and estradiol
from Revalor-XS implant was monitored in urine of
treated animals and confirmed the sustained release of the
steroids in the animals throughout the experiment (Bianc-
otto et al. personal communication).
The urinary concentrations of drug residues (a-estradiol,
ß-estradiol, a-trenbolone and ß-trenbolone), in animals
treated with Revalor-XS are reported in Table 1. In the urine
of animals belonging to the control group, only endogenous
a-estradiol was detectable at the day 8, 22 and 29 at the
concentration of (0.97 ± 0.22) lg l-1; (1.43 ± 0.24)lg l-1
and (1.06 ± 0.12) lg l-1, respectively.
3.1 Sample preparation
Blood sample preparation for LC–MS metabolomics is
one of the most challenging; blood is a complex matrix
which contains higher molecular weight species com-
paring to other biological matrices such as urine. Urine
has primarily been the matrix of choice for metabolomic
investigations related to anabolic practice detection in
rearing animals (Gallart-Ayala et al. 2015). Serum LC-
HRMS-metabolomics in this field has not been per-
formed yet, though serum might represent an interesting
matrix to investigate, in order to assess its complemen-
tarity to urine and its relevance for screening anabolic
practices in bovines, highlighting the novelty of the
current investigation.
Due to the wide chemical diversity of potential
metabolites a complete holistic overview using meta-
bolomics is not possible and decisions have to be made as
to which part of the metabolome is to be investigated.
The sample extraction procedure employed herein pre-
sents the advantage of obtaining both polar and non-polar
fractions of the serum, with the lower CHCl3 phase to
further serve for lipidomics investigations, where appro-
priate. In the scope of the present study, we set out to
investigate low-molecular-weight metabolites present in
the polar fraction of implanted and non-implanted bovine
serum. Bovine sera were investigated at day 8, 22 and 29
post-implantation, as two to 4 weeks growth of promoter
treatment is usually the period used by those involved in
such illegal practices.
3.2 Quality of LC-HRMS data
As a quality control procedure, an isotope labeled standard
mixture consisting of Leucine-5,5,5-d3, L-tryptophan 2,3,3
d3, Indole-2,4,5,6,7,3-acetic acid d5 and 1,4-tetra-
decanedioic acid d24 (1.25 ng ll
-1) was used. It was added
to each serum sample before LC-HRMS and served to
evaluate the retention time stability, the consistency of
signal intensities, the mass accuracy within and between
sequences, and eventual drifts in instrumental sensitivity.
Deviation from standard accurate mass remained below
5 ppm and no significant drift in retention time was noticed
within and between sequences. A pooled quality control
(QC) sample, derived from the complete study population
was also employed in order to check for consistency during
analysis. QCs were injected at the beginning (n = 4), the
end and also along the analytical run (n = 6 samples
bracketed by QC).
These measures have been taken to ensure that differ-
ences in the fingerprints would not be caused by analytical
variability but would reflect metabolome modifications
upon Revalor XS administration.
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3.3 Serum metabolomics profiling in HESI polarity
switch mode and selection of metabolites
of interest
The chromatographic separation was achieved via a recent
stationary phase called Charged Surface Hybrid (CSH)
C18. In CSH technology, a well controlled surface charge
is applied to the packing material. This low level charge
greatly improves the peak shape, retention and loading
behavior of ionized compounds in reverse phase separa-
tions. Other advantages include: improved batch-to-batch
reproducibility, rapid column re-equilibration, excellent
stability at low pH and a wide range of selectivity.
In the scope of the present study, reverse phase conditions
combined to electrospray ionization in polarity switch mode
(?/-) were implemented, as recognized to be the more open
in terms of application range and suited for the detection of
markers of anabolic practices (Dervilly-Pinel et al. 2011;
Courant et al. 2009, 2012). In relation to the organic phase,
methanol was preferred to acetonitrile. As reported by Dunn
et al. (2011), acetonitrile can present problems with elevated
background and reduced sensitivity at high acetonitrile
concentrations. Elution with methanol also proved to be a
good compromise in terms of price, background noise and
chromatographic separation (supplementary Fig. 1). Peaks
for the isotope labeled standards were already visible on the
total ion chromatogram (TIC) when elution was performed
with a methanol/water gradient instead of acetonitrile/water;
this rapid and visual check up was deemed useful for our
quality control procedure. For these reasons, metabolic
profiling of serum samples was performed in the study using
a methanol/water gradient. Figure 1 illustrates representa-
tive TICs obtained in LC-HRMS from control and treated
cattle (Fig. 1a, b, respectively). The complex interplay
between solvent, stationary phase and solute that enacts a
separation in RPLC was recently addressed through a com-
parison of methanol/water and acetonitrile/water systems.
The effects of acetonitrile/water and methanol/water as
mobile phase in reversed-phase liquid chromatography was
studied more in detail by molecular simulation and reported
by Rafferty et al. (2011).
We examined 96 serum samples from Revalor-XS
treated and non-treated bovine (day 8, day 22 and day 29
post-implant), in the building of predictive and screening
models. Sequences for each treatment day (day 8, day 22,
day 29) were first analyzed separately as described in
Sect. 2.6. Metabolic fingerprints generated in positive and
negative ionization mode were combined to build ‘posneg’
models for each treatment day.
The OPLS fit criteria were found to be the following:
R2(X) = 0.81, R2(Y) = 0.99, and Q2(Y) = 0.98 at day 8
(27 animals), R2(X) = 0.84, R2(Y) = 0.96, and
Q2(Y) = 0.90 at day 22 (29 animals), R2(X) = 0.73,
R2(Y) = 0.96, and Q2(Y) = 0.93 at day 29 (32 animals).
CV-ANOVA p values were equal to: 5.417 9 10-15 at day
8, 3.142 9 10-8 at day 22 and 2.770 x 10-13 at day 29. As
expressed by these high values, the models demonstrated
good descriptive and predictive performances.
Subsequently, the MetaXCMS application was imple-
mented to highlight common features across the treatment
period with the aim of building a global model. Venn
diagrams revealed 1689 features were common between
day 8, day 22 and day 29 samples in negative mode,
compared to 1828 common features in positive mode
(supplementary Fig. 2).
Ions displaying a CV below 30 % in QC samples were
retained for further statistical analysis; application of this
filter led to the selection of 1105 ions in negative mode and
1209 ions in positive mode. To remove between-batch
offsets and drifts, data were normalized following the
procedure described by van der Kloet et al. (2009),
assuming that the measurement errors in a single batch are
randomly distributed, and that different batches can be
compared and corrected using the average or median value
of the QC samples in a batch.
The normalized data matrix contained features charac-
terized by their accurate m/z, retention time, fold change,
and p value. A non-supervised PCA provided an overview
of the data structure; QC samples from all three treatment
periods were well-clustered, ensuring that further separa-
tion observed would reflect metabolome modifications
upon Revalor XS administration, and not analytical var-
iability. The resulting OPLS model (Fig. 2) further allowed
the selection of 26 discriminating ions, i.e., the most sig-
nificant to the model when comparing C and T animals.
These ions displayed mass-to-charge ratios ranging from
93 to 617 Da and retention time ranging from 82 s
(1.37 min) to 1,034 s (17.23 min).
The model exhibited good descriptive and predictive
abilities, as expressed by high values of R2(X) = 0.69,
R2(Y) = 0.891 and Q2(Y) = 0.842 parameters. The OPLS
model shows that most of the serum samples from C ani-
mals have coordinates opposed to serum samples from T
animals. Only one sample, control animal # 14 at day 29
Table 1 Urinary concentrations of a-estradiol, ß-estradiol, a-tren-
bolone and ß-trenbolone determined in animals treated with Revalor-
XS
Sampling
day
a-estradiol b-estradiol a-trenbolone b-trenbolone
8 2.69 ± 0.41 ND 2.06 ± 0.33 0.49 ± 0.04
22 3.86 ± 0.47 0.07 ± 0.02 2.02 ± 0.28 0.26 ± 0.03
29 3.47 ± 0.28 0.12 ± 0.02 1.42 ± 0.18 0.27 ± 0.02
The table reports mean concentration values of drug residues (lg l-1)
and the associated standard error
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(four weeks post implant), could not be discriminated from
the treated animals’ population. In addition, looking at the
OPLS plot, it seems that, within the T group, samples
collected 8 days post implant formed a separate cluster
from those of day 22 and day 29. This difference might be
due to the growth of the animals or the result of intense
metabolic perturbation a week following administration.
As reported by Saccenti et al. (2013), (O)PLS techniques
can over fit the dataset and this has to be controlled by using
appropriate cross-validation strategies. Thereby, the vali-
dation of the global model created was undertaken. The
robustness of the model was assessed using CV-ANOVA,
permutation test and cross validation (1/3 2/3 prediction)
analysis. The p-value calculated from the CV-ANOVA was
equal to 1.26 9 10-25 suggesting that the differences
observed through the model are significant. As further
evidenced in Fig. 3, permutation test and cross validation
(1/3 2/3 prediction) achieved satisfactory results. The cross
validation consisted in eliminating one-third of randomly
selected samples from the model and predicting their status
(or class) on the newly established model. This validation
step further confirmed the descriptive and predictive capa-
bilities of our global model, as demonstrated by high values
of R2(X) = 0.731, R2(Y) = 0.892, Q2(Y) = 0.842
parameters. In relation to the permutation test, the rationale
behind it was to ensure that the results were not due to a
chance factor. The goodness of fit of the original model was
compared to the goodness of fit of several models based on
data where the order of the sample classes had been ran-
domly permuted, while the data set was kept intact. It can be
drawn from Fig. 3 that the multivariate model is valid,
robust, and reflects a proper discrimination between control
and steroid treated populations up to four weeks post steroid
implant administration.
The next step was to generate a predictive model for
screening purposes. Finally, metabolites of further interest
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Fig. 1 Typical Total Ion Chromatograms obtained from serum of a control and b Revalor XS implanted bovine under RPLC-HESI-
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Fig. 2 Score plot for OPLS
model based on 26 selected ions
from the HESI?/HESI-
dataset. Control samples are
represented by green triangles;
serum samples from treated
animals collected on day 8, day
22 and 29 are represented by red
triangles (Color figure online)
Fig. 3 Validation of dataset
presented in Fig. 2 by
permutation test
Fig. 4 Results from a weighted
equation based on a suspicion
threshold using the contribution
of 9 discriminant metabolites
highlighted from multivariate
models. Control samples (C) are
represented by triangles and
Revalor XS implanted
(T) animals by circles
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were selected based on their coefficient plot in both
OPLS and PLS models, as evidenced in supplemen-
tary Fig. 3; the error bars indicate the confidence intervals
of the coefficients. The coefficient is significantly
(p\ 0.05) above the noise, when the confidence interval
does not include zero; the application of this principle led
to the selection of 9 ions of interest (supplementary
Fig. 4) amongst the 26 ions used in the previous multi-
variate model. Six of these ions exhibited higher intensi-
ties in the T group, while the 3 others showed an opposite
trend.
The putative markers highlighted in this serum meta-
bolomics study are different from the markers reported by
Jacob et al. (2014) in the frame of urinary fingerprinting
subsequent to the same steroid treatment. This proves that
urine and serum can be considered as complementary
matrices.
3.4 Predictive model for screening
The predictive model for screening purposes was based on
a weighted equation including individual abundance of the
9 ions of interest as follows (Eq. 1).
Y ¼ 0:284511  M93T748½  þ 0:25078  M108T769½ 
þ 0:246162  M152T768½   0:266365  M194T576½ 
 0:178207  M297T894½   0:351371  M299T719½ 
þ 0:257659  M327T659½   0:601153  M587T1037½ 
 0:32375  M617T1034½ 
ð1Þ
The equation determines the coordinates of a given
sample in the model, based on individual measured abun-
dance of each biomarker. As illustrated on Fig. 4, the
application of the equation to the 82 samples of the study
(41 control and 41 treated animals) provides very good
visual discrimination of treated and control sample groups.
Additionally, a screening criterion for Revalor XS
abuse has been established. It takes into account a thresh-
old which was determined as the mean value of all control
samples plus two or three times the standard deviation
(xcontrol ? 2r) or (xcontrol ? 3r) which corresponds to 95
and 99 % level of confidence, respectively. Such an
approach has already been successfully proposed for the
implementation of screening criteria in the context of ste-
roid abuse in horses (Kaabia et al. 2014) or b-agonists
administration to bovines (Dervilly-Pinel et al. 2014).
Table 2 Putative metabolites associated to the screening model
Metabolites Mass/charge
ratio
RT (s) Adduct Day 8 Day 22 Day 29 Up- or
down-
regulated
Putative
metabolites
Fold
Change
P value Fold
Change
p value Fold
Change
p value
M108T769 108.082126 768.524 [M-H-
CO2]-
1.6 0.00854 2.5 0.00012 1.8 0.00046 Up 4 Metabolites
returned from
Metlin and
HMDB search
including
Dopamine and
p-Octopamine
M152T768 152.0719918 768.459 [M-H]- 1.6 0.01157 2.3 0.00023 1.8 0.00005 Up 4 metabolites
returned from
Metlin and
HMDB search
including
Dopamine and
p-octopamine
M93T748 93.0347159 747.86 [M-H-
CO2]-
1.2 0.00851 1.9 0 1.3 0.0075 Down 16 Metabolites
returned from
Metlin and 10
from HMDB
search including
Dopaquinone
M194T576 194.046319 576.468 [M-H]- 1.2 0.17523 3.4 0 1.1 0.43775 Down
M327T659 327.0884667 658.505 2.2 0.00002 2.6 0 1 0.81675 Up
M297T894 297.17142 893.906 8.6 0 1.3 0.16684 1.1 0.35961 Down
M587T1037 587.3609458 1,037.48 1.2 0.10503 3.5 0.00001 3.6 0 Down
M617T1034 617.371632 1,033.89 2 0.00412 1.8 0.00982 4 0 Down
M299T719 299.1094991 719.15 4.1 0 1 0.75621 1 0.68109 Down
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As illustrated in Fig. 4 and based on the 99th percentile
level confidence, the model correctly predicts C and T
samples, and lead to no false non-compliant (false positive)
nor false compliant (false negative) animals. Whilst con-
sidering the 95th percentile level of confidence, the model
resulted in 2.38 % of false non-compliant rate; the false
non-compliant animal was the same animal already high-
lighted in the multivariate model, i.e., control animal # 14
at day 29. However, no false compliant samples were
observed. Although further validation steps including
Fig. 5 a LC-HR MS/MS analysis of Dopamine chemical standard under identical experimental conditions, using a Q-Exactive mass
spectrometer; b screenshot of the MS/MS spectrum of Dopamine in Metlin database
10
additional samples (both control and treated) is required to
assess the robustness and performances of the selected
markers—which was not the purpose of the present
research—the established model exhibit preliminary
interesting performances, in good agreement with the
Commission Decision 2002/657/EC (false compliant rate
below 5 % required) implying that serum is also a matrix
of interest for screening anabolic practices in bovine.
3.5 Tentative identification of candidate biomarkers
Whatever the objectives of a metabolomic study, one
critical step consists in the structural identification of mass
spectrometric features revealed by statistical analysis and
this remains a real challenge. Indeed, this requires both an
understanding of the studied biological system, the correct
use of various analytical information (retention time,
molecular weight experimentally measured, isotopic
golden rules, MS/MS fragment pattern interpretation), or
querying online databases (Courant et al. 2012).
First, the metabolites of interest were identified by
searching freely available online databases using accurate
masses obtained from HRMS experiments. Metabolite hits
were taken into account only when they were found by
both Metlin and HMDB databases. Among the 9 putative
biomarkers, hits were found for 3 of them, i.e., M108T769,
M152T768 and M194T576 (Table 2). Results generated
were assessed in relation to metabolites physiochemical
properties such as retention times, log P, and matrix of
occurrence. M108T769 and M152T768 were found to have
structural similarities with Dopamine, Octopamine and two
other isomers, whilst M194T576 was found to have simi-
larities with Dopaquinone and nine isomers.
However, in terms of physiochemical properties, these
matches do not agree with the retention time of our
putative biomarkers. Metabolite hits obtained from the
database query tend to be hydrophilic molecules with a
logP below zero, thus they would elute early under our
experimental conditions. To confirm this, dopamine, a
representative chemical standard of this cluster was pur-
chased and analyzed under identical experimental condi-
tions and proved to elute earlier (1.21 min & 73 s) as
suspected (&769 s) (Fig. 5a). Successful standard char-
acterization of dopamine was achieved through MS/MS
fragmentation using a Q-Exactive mass spectrometer and
compared to dopamine MS/MS spectrum available in
Metlin database (Fig. 5b).
It is important that database search results are followed
up by comparison with their standard compound when
available. In our case, database matches were not con-
firmed using chemical standards, which lead to the classi-
fication of our metabolites to levels 2 and 3 according to
the current MSI reporting standards.
4 Concluding remarks
Our primary aim in this study was to investigate serum as an
alternative to urine to establish a metabolomics model to
screen for Revalor XS misuse in animal breeding. In
summary, the resulting multivariate models displayed good
descriptive and prediction capabilities and could serve as
future tools for the classification of Revalor XS implanted
and non-treated bovine. Furthermore, a weighted equation
using individual abundance of 9 putative biomarkers suc-
ceeded in screening animal status up to four weeks post
steroid implant administration, a period usually employed by
those involved in illicit practices. The rate of false compliant
samples using the equation was equal to 0 %, in accordance
with Decision 2002/657/EC. The performance of the
screening model was therefore considered fit for purpose.
Our data implies that serum should also be considered as
a matrix of interest for screening anabolic practices in
bovines. Further prospective studies including a greater
number of control and treated animals might be interesting
to reinforce the screening model presented here.
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